10-K: Mereo BioPharma's Setrusumab Misses Phase 3 Fracture Endpoints

Mereo BioPharma Group PLC reported its 2025 annual results, revealing Setrusumab's Phase 3 trials for Osteogenesis Imperfecta failed primary fracture reduction endpoints, alongside continued operating losses and a Nasdaq minimum bid price non-compliance notice.

Summary

• Setrusumab's Phase 3 Orbit and Cosmic studies in pediatric and young adult Osteogenesis Imperfecta (OI) patients did not achieve statistical significance for their primary endpoints of reducing annualized clinical fracture rates.
• Both Setrusumab studies, however, achieved secondary endpoints of statistically significant and substantial improvements in Bone Mineral Density (BMD) compared to placebo and bisphosphonates, respectively.
• Additional analyses for Setrusumab indicate a reduction in vertebral fractures and a positive impact on pain and mobility/sports activity in pediatric and teen patients.
• Alvelestat's Phase 2 studies (ASTRAEUS and ATALANTa) demonstrated statistically significant changes in Neutrophil Elastase (NE) activity and biomarkers of disease severity.
• Regulatory guidance for Alvelestat's Phase 3 includes St. Georges Respiratory Questionnaire (SGRQ) total score as the primary endpoint for U.S. approval and lung density by CT scan for EU approval (with a relaxed p-value <0.1); an EMA Pediatric Investigation Plan (PIP) full waiver was granted.
• Vantictumab, an early-stage rare disease program for Autosomal Dominant Osteopetrosis Type 2 (ADO2), was licensed to shibio, with Mereo retaining European and U.K. commercial rights; shibio reported promising preclinical data and expects to file an Investigational New Drug (IND) application in the second half of 2026.
• Leflutrozole was globally licensed to ReproNovo, generating a $0.5 million milestone payment in 2025 for the initiation of a Phase 2 trial, with potential for up to $63.8 million in additional milestones and tiered mid-single digit royalties.
• Navicixizumab was globally out-licensed to Feng Biosciences, with potential for up to $300 million in future milestones and tiered royalties.
• The company reported a net loss of $41.9 million for the year ended December 31, 2025, a slight improvement from $43.3 million in 2024, with an accumulated deficit of $501.0 million.
• Cash and cash equivalents stood at $41.0 million as of December 31, 2025, with an expectation to fund operations into mid-2027.
• Mereo BioPharma received a notice from Nasdaq on February 17, 2026, regarding non-compliance with the minimum bid price requirement of $1.00 per ADS.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with significant negative implications from the Setrusumab Phase 3 primary endpoint miss, which is a major setback for its lead rare disease candidate. While there are some positive biomarker data and strategic partnerships, the immediate future is clouded by the need for additional funding and Nasdaq non-compliance, leading to a cautious outlook.

Positives

• Setrusumab's Phase 3 Orbit and Cosmic studies achieved statistically significant and substantial improvements in Bone Mineral Density (BMD) compared to placebo and bisphosphonates, respectively.
• Additional analyses of Setrusumab data indicate a reduction in vertebral fractures and a positive impact on pain and mobility/sports activity in pediatric and teen patients.
• Alvelestat's Phase 2 ASTRAEUS and ATALANTa studies demonstrated statistically significant changes in NE activity and biomarkers of disease severity, supporting progression to Phase 3.
• Alvelestat received favorable regulatory guidance for its planned Phase 3 study, including alignment with the FDA on SGRQ total score as a primary endpoint for U.S. approval and EMA guidance that lung density by CT scan may be sufficient for EU approval with a relaxed p-value.
• The EMA granted a full Pediatric Investigation Plan (PIP) waiver for Alvelestat, meaning no pediatric studies are required.
• The company successfully out-licensed Vantictumab to shibio, retaining European and U.K. commercial rights, and shibio reported promising preclinical data.
• A $0.5 million milestone payment was received in 2025 for the initiation of a Phase 2 trial for Leflutrozole, following its global out-licensing to ReproNovo.
• Net loss decreased to $41.9 million in 2025 from $43.3 million in 2024.
• Benefit from research and development tax credits increased to $1.9 million in 2025 from $1.6 million in 2024.
• Existing cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into mid-2027.

Negatives

• Setrusumab's Phase 3 Orbit and Cosmic studies did not achieve statistical significance against their primary endpoints of reduction in annualized clinical fracture rate.
• The Orbit study observed a low fracture rate in the placebo group, which may have contributed to the failure to meet the primary endpoint.
• The company continues to incur significant operating losses, with a net loss of $41.9 million in 2025 and an accumulated deficit of $501.0 million.
• Mereo BioPharma received a notice from Nasdaq on February 17, 2026, for non-compliance with the minimum bid price requirement of $1.00 per ADS.
• A net foreign exchange transaction loss of $6.3 million was recorded in 2025, compared to a gain of $1.2 million in 2024.
• Interest income decreased by $0.9 million in 2025 due to lower interest rates and reduced cash and cash equivalents balances.

Risks

• Limited operating history and no revenue generated from product sales to date.
• Need for substantial additional funding to complete product development and commercialization; inability to raise capital could force delays or program elimination.
• Heavy dependence on the success of Setrusumab and Alvelestat, with no assurance of regulatory approval.
• Future growth and ability to compete depend on retaining key personnel and recruiting additional qualified personnel.
• Dependence on patient enrollment in clinical trials, particularly for rare disease indications, which may be slower than anticipated.
• Exposure to costly and damaging product liability claims during clinical testing or commercialization, potentially exceeding insurance coverage.
• Lengthy, time-consuming, and inherently unpredictable regulatory approval processes by the FDA, EMA, MHRA, and other authorities.
• Enacted and future healthcare legislation may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and may affect pricing.
• Operating in a highly competitive and rapidly changing industry, with larger competitors possessing greater resources.
• Inability to develop own sales, marketing, and distribution capabilities or enter into effective business arrangements for commercialization.
• Successful commercialization depends on adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers.
• Existing and future product candidates may not gain market acceptance, compromising revenue generation.
• Reliance on partners to develop and commercialize licensed products; risks of partners failing to secure funding, satisfy obligations, or terminating agreements.
• Reliance on third parties (CROs, CMOs) to conduct clinical trials and manufacturing, posing risks of contractual failures, delays, or quality issues.
• Reliance on patents and other intellectual property rights, with challenges in obtainment, enforcement, defense, and maintenance.
• Potential for third-party claims alleging infringement of patents and proprietary rights, leading to costly litigation or delays.
• Business and operations may suffer from information technology system failures, cyberattacks, or deficiencies in cybersecurity.
• Compliance with the domestic reporting regime under the Exchange Act (post-FPI status) incurs significant legal, accounting, and other expenses, and requires substantial management time.
• May not satisfy Nasdaq's requirements for continued listing, potentially leading to delisting and adverse impact on liquidity and market price of ADSs.
• Failure to establish and maintain effective internal controls could materially affect business and stock price.
• Potential for the company to be classified as a Passive Foreign Investment Company (PFIC) for U.S. investors, resulting in adverse tax consequences.
• Manufacturing tests of Setrusumab have shown it may cause an opalescence appearance to the liquid antibody formulation, though it does not impact potency or effectiveness.
• Business is subject to unstable market, economic, political, regulatory, and other risks in international operations, including supply chain disruptions and geopolitical events.
• Changes in tax rates, unavailability of certain tax credits or reliefs, or exposure to additional tax liabilities could adversely affect financial results.
• Brexit continues to create uncertainty and may negatively impact the business due to divergent regulatory requirements.
• Interim, top-line, and preliminary data from clinical trials and preclinical studies may change as more data become available.
• Product candidates may have serious adverse, undesirable, or unacceptable side effects, potentially delaying or preventing marketing approval or leading to withdrawal.
• Disruptions at the FDA and other government agencies due to funding shortages, staffing limitations, or other factors could delay product development or commercialization.
• Product candidates approved as biologics may face competition sooner than anticipated from biosimilars.
• The increasing use of artificial intelligence (AI)-based software introduces additional risks, including flawed algorithms, biased data, unclear intellectual property rights, and cybersecurity vulnerabilities.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it invests in research and development, seeks regulatory approvals, and potentially commercializes product candidates. Expenses are anticipated to increase substantially due to ongoing development activities, manufacturing scale-up, intellectual property protection, and personnel expansion. Existing cash and cash equivalents are projected to fund operations into mid-2027, but additional external funding will be required to complete development plans and potentially commercialize selected rare disease products. The company plans to pursue non-dilutive funding, public/private equity or debt financings, or other sources. Next steps for Setrusumab, including potential regulatory interactions, will be determined after further data analysis. The Alvelestat program is progressing towards a planned Phase 3 study, with non-dilutive financing options being evaluated. Shibio expects to file an IND for Vantictumab in the second half of 2026. The company anticipates claiming under the new Merged Scheme for R&D tax credits from 2025 onward, expecting a cash receipt in 2026. New EU pharmaceutical legislation, which could impact the industry, is expected to be fully applicable in 2028.

Management Comments

• "We intend to become a leading biopharmaceutical company developing innovative therapeutics that aim to improve outcomes for patients with rare diseases."
• "We believe that we are a preferred partner for pharmaceutical and biotechnology companies as they seek to unlock the potential in their development pipelines and deliver therapeutics to patients in areas of high unmet medical need."
• "We intend to continue to enter into strategic relationships that align our interests with those of pharmaceutical and biotechnology companies and that we believe to be mutually beneficial."
• "We expect that our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into mid-2027 at which point we will require additional capital."
• "We do not believe the new Merged Scheme could have a detrimental impact on our R&D tax credit for the year ended December 31, 2025, which we anticipate receiving in cash in 2026."
• "The Company intends to vigorously defend against this action [putative class action complaint]."

Industry Context

StockSavvy.ai notes that Mereo BioPharma operates in the highly competitive rare disease biopharmaceutical sector, characterized by high unmet medical needs and specialized regulatory pathways. The company's strategy of acquiring de-prioritized assets from larger firms is a common approach to leverage prior investment and accelerate development. The mixed Phase 3 results for Setrusumab highlight the inherent risks in late-stage clinical development, even for promising candidates, a challenge faced across the industry. The company's reliance on partnerships for global development and commercialization aligns with industry trends for smaller biotechs to mitigate financial and operational risks. The increasing regulatory scrutiny and cost containment measures, particularly in the U.S. and EU, will continue to pressure pricing and reimbursement for new therapies, impacting all players in the sector.

Comparison to Industry Standards

• Setrusumab (OI): Competes with Amgen and UCB's romosozumab (Evenity), approved for osteoporosis and in Phase 3 for OI; Transcenta Holding's blosozumab (licensed from Eli Lilly) for osteoporosis; BOOST Pharma's fetal-derived mesenchymal stem cell therapy (planning Phase 3); and Angitia Biopharmaceuticals' Sclerostin & Dickkopf-1 bispecific antibody (planning Phase 2). Mereo's Setrusumab missed primary fracture endpoints but showed significant BMD improvements, suggesting a potential differentiation in bone formation but not direct fracture reduction in the studied populations.
• Alvelestat (AATD-LD): Competes with four existing alpha-1 proteinase inhibitors (Prolastin-C from Grifols, Aralast from Shire/Takeda, Zemaira from CSL, Glassia from Kamada) and pipeline candidates like Kamada's recombinant AAT, Sanofi's SAR-447537 (rhAAT-Fc), Wave Life Sciences' WVE-0006 (RNA base-editing, partnered with GSK), Beam Therapeutics' BEAM-302 (genome editing), Krystal Biotech's KB-408 (inhaled gene therapy), and Korro Bio's RNA Base editing oligonucleotide therapy. Mereo's Alvelestat, an oral small molecule NE inhibitor, offers a potential convenience advantage over weekly intravenous augmentation therapies, with Phase 2 data showing biomarker efficacy and SGRQ improvement.
• Vantictumab (ADO2): Faces competition from SiSaf Ltd.'s pre-clinical CLCN7-targeting siRNA. As there are no approved therapies for ADO2, Vantictumab, with promising preclinical data from shibio, addresses a high unmet need but carries the inherent risks of early-stage development in a novel indication.
• Etigilimab (Advanced Solid Tumors): Operates in the highly competitive immuno-oncology space, competing with other anti-TIGIT agents from Roche, Merck, iTeos, GSK, BeOne Medicines, Arcus/Gilead, and Compugen, as well as combinations of existing cancer therapies (e.g., Yervoy and Opdivo, Opdivo or Keytruda with chemotherapy agents) and bispecific antibodies with anti-TIGIT arms (e.g., AstraZeneca's NSCLC program).
• Acumapimod (AECOPD): While no approved therapies specifically for AECOPD exist, it competes with established COPD treatments and pipeline candidates. Closest potential competitor is Merck & Co's nebulized and inhaled ensifentrine (Ohtuvayre), recently approved for COPD, Asthma, and Cystic Fibrosis. Other p38 MAP Kinase pathway inhibitors are in development by Poolbeg, Fulcrum, GEn1E Lifesciences, CervoMed, Kinarus, Neurokine, and Inovio for other indications, and ReAlta Life Sciences is in Phase 2 for a complement 1 sub-component inhibitor for AECOPD.

Legal Proceedings

• A putative class action complaint was filed on February 4, 2026, in the United States District Court for the Southern District of New York against the Company, its Chief Executive Officer, Denise Scots-Knight, and its Chief Scientific Officer, John Lewicki, alleging violations of federal securities law by making false and misleading statements regarding the company's business and operations. The company intends to vigorously defend against this action.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, increased stock price volatility due to clinical trial outcomes and Nasdaq non-compliance, and the financial and reputational risks associated with the putative securities class action.
• Patients with Osteogenesis Imperfecta (OI) may experience delays or changes in access to Setrusumab as a new therapy, given the missed primary endpoints in Phase 3 trials, despite positive bone mineral density improvements.
• Patients with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) may anticipate a new oral treatment option with Alvelestat progressing to Phase 3, offering potential convenience benefits over existing intravenous therapies.
• Employees may experience uncertainty related to program outcomes and future funding, but also potential growth opportunities if pipeline candidates advance and commercialization efforts succeed.
• Partners (Ultragenyx, shibio, ReproNovo, Feng Biosciences) are subject to shared development and commercialization risks, with their financial returns dependent on the success of the licensed product candidates and the terms of their agreements.
• Creditors and potential investors will closely monitor the company's liquidity, ability to secure additional funding, and progress in clinical development and regulatory approvals, especially in light of the Setrusumab results and Nasdaq listing status.

Next Steps

• Thoroughly analyze the data from the Phase 3 Orbit and Cosmic studies for Setrusumab to determine the next steps, including potential regulatory interactions, for its potential commercialization in the EU and U.K.
• Seek to secure a partnership and prepare for a potential Phase 3 clinical trial of Alvelestat for the treatment of severe AATD-LD.
• Shibio expects to file an Investigational New Drug (IND) application for Vantictumab in the second half of 2026.
• Continue to evaluate non-dilutive financing options for the development and potential commercialization of Alvelestat in AATD-LD.
• Explore out-licensing or sale opportunities with third parties for further clinical development and/or commercialization of non-core programs like Etigilimab and Acumapimod.
• Regain compliance with Nasdaq's minimum bid price requirement of $1.00 per ADS by August 17, 2026.
• Monitor and adapt to the new EU pharmaceutical legislation, expected to be fully applicable in 2028, and the U.K. clinical trials regulations amendment becoming applicable on April 28, 2026.

Key Dates

Recommendation

The failure of Setrusumab, a lead rare disease product candidate, to meet its primary endpoints in two Phase 3 studies is a significant clinical setback, despite positive secondary biomarker data. This outcome, combined with the company's ongoing operating losses, accumulated deficit, and the Nasdaq minimum bid price non-compliance, creates substantial uncertainty and downside risk for investors. While there are other pipeline assets and partnerships, the immediate future is clouded by the need for additional funding and the challenge of navigating regulatory pathways after a pivotal trial miss. A seasoned investor would likely view this as a signal to exit or significantly reduce exposure due to increased risk and diminished near-term catalysts.

Keywords

Biopharmaceutical, Rare Diseases, Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency, Setrusumab, Alvelestat, Clinical Trials, Regulatory Approval, NASDAQ, Biotech, Drug Development, Orphan Drug, Sclerostin Inhibitor, Neutrophil Elastase Inhibitor, ADO2, Vantictumab, Leflutrozole, Navicixizumab, Etigilimab, Acumapimod, SEC Filing, 10-K